Advertisement
Singapore markets close in 7 hours 20 minutes

  • Straits Times Index

    3,411.16
    +43.26 (+1.28%)
     

  • Nikkei

    40,338.51
    +263.82 (+0.66%)
     

  • Hang Seng

    17,841.77
    +72.63 (+0.41%)
     

  • FTSE 100

    8,121.20
    -45.56 (-0.56%)
     

  • Bitcoin USD

    62,013.61
    -816.75 (-1.30%)
     

  • CMC Crypto 200

    1,335.49
    -9.02 (-0.67%)
     

  • S&P 500

    5,509.01
    +33.92 (+0.62%)
     

  • Dow

    39,331.85
    +162.33 (+0.41%)
     

  • Nasdaq

    18,028.76
    +149.46 (+0.84%)
     

  • Gold

    2,339.30
    +5.90 (+0.25%)
     

  • Crude Oil

    83.11
    +0.30 (+0.36%)
     

  • 10-Yr Bond

    4.4360
    -0.0430 (-0.96%)
     

  • FTSE Bursa Malaysia

    1,601.81
    +3.85 (+0.24%)
     

  • Jakarta Composite Index

    7,125.14
    -7,139.63 (-50.05%)
     

  • PSE Index

    6,358.96
    0.00 (0.00%)
     

EXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing Conditions

Vandana Singh
·2-min read

PainReform Ltd (NASDAQ:PRFX) announced results from new studies demonstrating the superior in-vitro release (IVR) rates of PRF-110 compared to topical post-surgical pain management products available in the market.

These findings underscore PainReform’s commitment to advancing non-opiate pain relief options and mark a significant milestone in developing long-lasting pain management solutions.

Leveraging the latest IVR technology, which automates the testing of drug release from formulations over time, PainReform conducted comprehensive studies to evaluate the performance of PRF-110.

Over a 72-hour industry-standard duration and extending to 96 hours, PRF-110 exhibited higher rates of analgesic drug release compared to a market-leading post-surgical pain product.

ADVERTISEMENT

Results indicated that PRF-110 released between 34%-77% more drug over 96 hours under various testing conditions.

The results support PRF-110’s superior efficacy and its potential to extend the pain relief duration significantly.

By ensuring a more consistent and prolonged analgesic effect, PRF-110 aims to reduce the dependency on opiates for post-surgical pain management, the company said.

Last week, PainReform announced it reached the 50% enrollment target for the second part of the Phase 3 clinical trial of PRF-110 in bunionectomy. Over 200 patients have been enrolled.

In January, PainReform reported in vitro test results comparing the PRF-110 versus the industry leader as a topical analgesia for postoperative pain relief.

The in vitro tests were designed to mimic the spreadability attribute critically required for post-surgical topical applications.

PRF-110 demonstrated superior formulation properties concerning surface-tissue spreading and superior surface interaction with surgical tissue based on a slide test, which demonstrated sliding of the formulations down inclined, dry, and wet surfaces.

In phosphate-buffered saline, the sliding of PRF-110 was twice that of the competitor.

Price Action: PRFX shares closed at $1.74 on Monday.

"ACTIVE INVESTORS' SECRET WEAPON" Supercharge Your Stock Market Game with the #1 "news & everything else" trading tool: Benzinga Pro - Click here to start Your 14-Day Trial Now!

Get the latest stock analysis from Benzinga?

This article EXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing Conditions originally appeared on Benzinga.com

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.